Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
← catalyst calendarNCT07315113 · readout ≤ 134 d
Sponsored by Nuvectis Pharma, Inc. (industry) · NVCT — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
18estimated
Sites
6
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-12-18 | actual | When the study began enrolling |
| Primary completion | Dec 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jun 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2026-01-02 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-09 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- EGFR Mutation Positive Non-small Cell Lung Cancer
- EGFR Mutated Non-small Cell Lung Cancer Patients
Interventions
- Drug: NXP900
- Drug: Osimertinib
Primary outcomes
what the primary-completion date above is the date OFNumber of patients with treatment related adverse events and/or clinical laboratory abnormalities
measured Up to 30 days post treatment
Objective response rate (ORR)
measured Up to approximately 12 months
Duration of Response (DoR)
measured Up to approximately 12 months
Disease Control Rate (DCR)
measured Up to approximately 12 months
Permalink · NVCT's whole pipeline · Catalyst calendar · Every registered study · What changed